DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth is currently undergoing a transition from a consumer to an enterprise market focus, which is expected to lead to stronger financial performance and potential multiple expansion. The company's patient offerings, including a physical device, smartphone app, and individual coaching, provide a unique and comprehensive solution for managing chronic conditions that is cost-effective for both patients and healthcare systems. The company's recent strong revenue performance in the B2C segment and continued progress in its contract phase with a new hospital system channel partner indicate potential for continued growth and eventual cash flow breakeven in mid-2027.

DarioHealth is showing promising signs in its B2C revenue, with management attributing the growth to its MSK solutions and international expansion. However, their B2B2C accounts and pipeline additions may not be enough to sustain strong revenue growth, and their target of break-even by mid-27 may be too optimistic given their expected losses in the next few years. There is also a risk that DRIO may not be able to cross-sell their products and services to legacy Twill customers and may not see lower operating expenses as hoped.